SSG
EDIT icon

Summit Securities Group’s Editas Medicine EDIT Stock Holding History

Summit Securities Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-178
Closed -$206 – 1167
2025
Q1 		$206 Buy
+178
New +$262 ﹤0.01% 734
2023
Q4 		– Sell
-5,679
Closed -$44K – 730
2023
Q3 		$44K Buy
+5,679
New +$48.7K ﹤0.01% 294

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Summit Securities Group's EDIT Position: Q2 2025 in Review

Summit Securities Group sold out of Editas Medicine (EDIT) in Q2 2025, closing a stake of 178 shares — an estimated $206 sold.

Summit Securities Group first reported a position in EDIT in Q3 2023 and held it in 2 quarters. The position peaked at $44K in Q3 2023. 193 funds tracked by Wall St. Rank hold EDIT as of Q2 2025.

  • Summit Securities Group reported no remaining Editas Medicine position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 178 Editas Medicine shares in Q2 2025, an estimated $206.
  • Summit Securities Group first reported a position in Editas Medicine in Q3 2023 and held it in 2 quarters.
  • Summit Securities Group's Editas Medicine position peaked at $44K in Q3 2023.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.